-transparent.png){kind=logo}
Malignant non-Hodgkin's lymphoma (NHL) patients were enrolled and analyzed retrospectively in 2 successive study groups. The first group consisted of 57 patients divided into low- and high-grade malignant NHL according to the Kiel classification, the second one included 104 patients divided into low-, intermediate-, and high-grade malignant NHL. The more individualized and more intensive polychemotherapy of the 2nd group yielded clearly better treatment results compared to the first group, especially in high-grade malignant NHL. The complete remissions rose from 32% to 59%, the recurrence rates fell from 62% to 20%, the 5-year survival time of patients under age 30 increased from 0 to 48%. In intermediate-grade malignant NHL, intensive therapy yield results that are as beneficial as those of mild therapy in low-grade malignant NHL (5-year survival rate 62% and 65%, respectively).
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
March 1980,
Minerva medica,
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
April 1980,
Minerva medica,
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
January 1996,
Acta oncologica (Stockholm, Sweden),
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
December 1978,
Minerva medica,
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
September 1977,
Cancer treatment reports,
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
January 1979,
Annals of internal medicine,
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
January 1993,
Revista do Hospital das Clinicas,
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
March 2005,
MMW Fortschritte der Medizin,
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
September 1981,
Clinical radiology,
H Jahn, and
K Ruffert, and
G Syrbe, and
R Kühn, and
D Jorke
May 1991,
Orvosi hetilap,
